A double-blind, randomised, placebo-controlled clinical study to evaluate the efficacy and safety of N-Acetyl-GED-0507-34-LEVO gel, 1 and 2%, applied once daily for 12 weeks in patients with mild to moderate facial acne vulgaris
Latest Information Update: 29 Mar 2018
At a glance
- Drugs GED 0507 34 Levo (Primary)
- Indications Acne vulgaris
- Focus Therapeutic Use
- 08 Feb 2017 Status changed from recruiting to completed.
- 28 Jul 2016 New trial record